Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 12

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 12
---
 Puglisi and Associates. Our agent for service in the United States
is Donald J. Puglisi of Puglisi and Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711. Our Depositary Shares
are traded on the NASDAQ Capital Market under the symbol “BDRX.”

Our corporate website is located
at www.biodexapharma.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

<div align='center'>Implications of Being a Foreign Private Issuer</div>

We are incorporated as a public limited company in England and Wales,
and we are deemed to be a “foreign private issuer” for the purposes of the reporting rules under the Securities Exchange Act
of 1934, as amended, or the Exchange Act. In our capacity as a foreign private issuer, we are exempt from certain rules under the Exchange
Act that would otherwise apply if we were a company incorporated in the United States, including:

| · | the requirement to file periodic reports and financial statements with the SEC as frequently or as promptly 
 as United States companies with securities registered under the Exchange Act;                               |

| · | the requirement to file financial statements in accordance with accounting principles generally accepted 
 in the United States, or U.S. GAAP;                                                                      |

| · | the proxy rules, which impose certain disclosure and procedural requirements for proxy solicitations; 
 and                                                                                                   |

| · | the requirement to comply with Regulation FD, which imposes certain restrictions on the selective disclosure 
 of material information.                                                                                     |

In addition, our officers,
directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery provisions of Section
16 of the Exchange Act and the rules under the Exchange Act with respect to their purchases and sales of our Ordinary Shares. Accordingly,
an investor may receive less information about us than it would receive about a public company incorporated in the United States.

Additionally, we elect to
follow certain home country corporate governance practices instead of those otherwise required under the listing rules of NASDAQ.

<div align='center'>Offerings Under This Prospectus</div>

Under this prospectus,
we may offer Ordinary Shares, including Depositary Shares representing our Ordinary Shares, various series of debt securities or warrants
or rights to purchase any of such securities, either individually or in units, with a total value of